Form 4: AEON Biopharma Director Marc Forth Receives Significant Restricted Stock Unit Grant

AEON Biopharma, Inc. Director Marc Forth was granted 370,370 Restricted Stock Units (RSUs) on May 21, 2025, as part of his compensation, aligning his interests with shareholder value.

Summary

• Marc Forth, a Director at AEON Biopharma, Inc. (AEON), reported the acquisition of 370,370 Restricted Stock Units (RSUs).
• The transaction date for this grant was May 21, 2025.
• Each RSU will be settled in cash based on the fair market value of AEON's Class A Common Stock on the applicable vesting date.
• The RSUs are subject to a vesting schedule where 1/3rd will vest on each anniversary of May 21, 2025.
• Following this transaction, Marc Forth directly beneficially owns 370,370 derivative securities (RSUs) convertible into Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reports a standard compensation grant to a director, which is generally a positive sign of management alignment and commitment, without any negative financial or operational news.

Positives

• The grant of Restricted Stock Units to Director Marc Forth aligns his financial interests with the long-term performance of AEON Biopharma, Inc. and its shareholders.
• The vesting schedule over multiple years indicates a commitment to retaining key management and directors.

Risks

• The value of the RSUs upon vesting is dependent on the future fair market value of AEON's Class A Common Stock, introducing market risk.
• The cash settlement nature means the director will receive cash, not shares, which could impact direct share ownership and voting power.

Future Outlook

The Restricted Stock Units granted to Director Marc Forth are scheduled to vest in three equal annual installments, beginning on May 21, 2026, and continuing on each anniversary of May 21, 2025, indicating a multi-year compensation and retention strategy.

Industry Context

This RSU grant is a standard form of executive and director compensation in the biopharmaceutical industry, designed to incentivize long-term performance and align management interests with shareholder returns. Such grants are common practice for publicly traded companies to attract and retain talent.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a compensation vehicle is a common practice across the biopharmaceutical sector, similar to companies like Amgen (AMGN) or Gilead Sciences (GILD) which frequently use equity awards to compensate their directors and executives.
• The vesting schedule of 1/3rd annually over three years is a typical structure for RSU grants, comparable to those seen at many peer companies, ensuring a sustained commitment from the recipient.
• The grant size of 370,370 RSUs, while specific to AEON's compensation philosophy and the director's role, falls within the range of significant equity awards granted to non-executive directors in companies of similar market capitalization within the biotech space, reflecting a substantial alignment incentive.

Related Party Transactions

• The grant of 370,370 Restricted Stock Units to Director Marc Forth constitutes a related party transaction, as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholder value creation, as the value of the compensation is tied to the company's stock performance.
• Management/Directors: Provides a significant incentive and compensation component for Director Marc Forth, encouraging long-term commitment to the company.

Next Steps

• The RSUs will vest in three annual installments, with the first vesting occurring on May 21, 2026, and subsequent vestings on the anniversaries of May 21, 2025.
• Upon vesting, the RSUs will be settled in cash based on the fair market value of AEON's Class A Common Stock.

Key Dates

Recommendation

Keywords

AEON Biopharma, AEON, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership